|
Vaccine Detail
pcDNA3-LiP0 |
Vaccine Information |
- Product Name: DNA Vaccine encoding LIPO-A Protein of L. infantum
- Vaccine Ontology ID: VO_0004197
- Type: DNA vaccine
- Status: Research
- Antigen: LiP0
- LIPO-A
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Vector: Eukaryotic expression plasmid pcDNA3 (Invitrogen, San Diego, Calif.) (Iborra et al., 2003)
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: In DNA immunization experiments, mice were inoculated twice intramuscularly (i.m.) in both quadriceps with 100 μg of DNA (50 μg per leg) of either pcDNA3-LiP0 or pcDNA3 (controls) in a total volume of 100 μl of PBS. When “prime-boost” immunization was carried out, two inoculations of DNA and two inoculations of recombinant protein were administered. In all groups, the mice were inoculated at 2-week intervals (Iborra et al., 2003).
- Challenge Protocol: Two weeks after the final inoculation, immunized mice were challenged with 5 × 10^4 stationary-phase promastigotes of L. major that were suspended in 50 μl of PBS and injected into the left hind footpad (Iborra et al., 2003).
- Efficacy: Three weeks after challenge, the parasite burden was found to be significantly lower in mice vaccinated with pcDNA3-LiP0 than in controls. Mice vaccinated with LiP0-DNA had a 99.1% reduction in the parasite burden 3 weeks after infection compared with mice vaccinated with control DNA (Iborra et al., 2003).
|
References |
Iborra et al., 2003: Iborra S, Soto M, Carrión J, Nieto A, Fernández E, Alonso C, Requena JM. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infection and immunity. 2003; 71(11); 6562-6572. [PubMed: 14573678].
|
|